Bevacizumab biosimilar (Boehringer Ingelheim)

N/A

Report date: 2026/03/23 20:03:44

Base Information

Drug NameBevacizumab biosimilar (Boehringer Ingelheim)
Drug Alias Name贝伐人源化单抗生物仿制药（勃林格殷格翰）贝伐人源化单抗生物类似药（勃林格殷格翰）贝伐珠单抗生物类似药（勃林格殷格翰）贝伐珠单抗生物仿制药（勃林格殷格翰）贝伐单抗生物类似药（勃林格殷格翰） +[7] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaUnited StatesUkraine +[29] 
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesC.H. Boehringer Sohn Ag & Co. Kg
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesC.H. Boehringer Sohn Ag & Co. Kg
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell LungColorectal Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A